Johan Heilborn

Johan Heilborn has a diverse work experience in the medical field. Johan started their career in 2003 as a Co-Founder at Lipopeptide, where they made novel discoveries in the functionality of The Human Antimicrobial Peptide LL-37. This company is now part of Pergamum. In 2008, they founded their own company, Heilborn Medical AB, where they served as Founder & Owner. In 2010, they became the Head of Tumor Section at Karolinska Hospital, a role they held until 2012. In 2012, they founded Hudcentrum Hagastaden AB and served as the CEO and Founder. Lastly, in 2014, they joined Dermicus as the Chief Medical Officer.

Johan Heilborn obtained their Doctor of Medicine (MD) degree from Karolinska Institutet, graduating between the years 1983 to 1989. Later on, from 2000 to 2005, they pursued further education at the same institution, Karolinska institutet, earning a Doctor of Philosophy (PhD). Johan'sPhD degree focused on the field of study in wound healing, antimicrobial peptides, and molecular biology.